Skip to main content
sec_filing· Regulatory

SRZN receives FDA accelerated designation by end of 2028

Market overview

Derived from Surrozen, Inc./DE (SRZN) (CIK 0001824893) 8-K filing analysis

Regulatory prediction market

Implied probability (Yes)
25%
Closes

About this prediction

Resolution criteria

Surrozen receives FDA Breakthrough Therapy or Fast Track designation for one of its lead candidates.

More Regulatory markets

Browse all Regulatory markets →

No one's made a Conviction call on this yet. Be the first to call it →
Loading…